U.S. FDA Clears the Motus GI Pure-VU Platform

Feb 14, 2022 By MarketDepth

Biotechnology Business Headlines Investing What's Hot

FDA Approval

Motus GI Holdings, Inc. (NASDAQ: MOTS) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration for the Pure-Vu® EVS System.

Up Premarket

Shares of Motus GI Holdings, Inc. (NASDAQ: MOTS) gained over 39% during the premarket trading session following the announcement.

“This FDA clearance of Pure-Vu EVS is expected to allow a greater number of physicians and hospitals to bring this important technology to their patients.”

Tim Moran, Chief Executive Officer

The Pure-Vu platform facilitates the cleaning of a poorly prepared colon to improve visualization during the colonoscopy procedure and is meant to improve the speed of set-up as well as enable physicians to rapidly overcome the challenges of poorly prepared colons during a colonoscopy.

“Pure-Vu EVS is much easier to use, and will be more physician and technician friendly. The set-up is significantly simpler, and the slimmer, more flexible design felt like I didn’t have an oversleeve on my scope.”

Neha Mathur, MD, Gastroenterologist, Houston, TX

The Pure-Vu EVS platform’s commercial launch is expected to take place in the first quarter of 2022.